Recombinant human IgA1 and IgA2 autoantibodies to type VII collagen induce subepidermal blistering ex vivo

Journal of Immunology

Volumn 193, Issue 4, 2014, Pages 1600-1608

  Recke, Andreas ^a   Trog, Luisa M ^a   Pas, Hendri H ^b   Vorobyev, Artem ^a   Abadpour, Aida ^a   Jonkman, Marcel F ^b   Van Zandbergen, Ger ^c   Kauderer, Claudia ^a   Zillikens, Detlef ^a   Vidarsson, Gestur ^d   Ludwig, Ralf J ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c PAUL EHRLICH INSTITUT   (Germany)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC PROTEIN; COLLAGEN TYPE 7; COMPLEMENT COMPONENT C3B; IMMUNOGLOBULIN A; IMMUNOGLOBULIN A ANTIBODY; REACTIVE OXYGEN METABOLITE; RECOMBINANT ANTIBODY; RECOMBINANT HUMAN IMMUNOGLOBULIN A1 ANTIBODY; RECOMBINANT HUMAN IMMUNOGLOBULIN A2 ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ANTIGEN ANTIBODY COMPLEX; ARTICLE; AUTOIMMUNE DISEASE; BLISTER; COMPLEMENT ACTIVATION; COMPLEMENT DEPOSITION; CONTROLLED STUDY; DERMOEPIDERMAL JUNCTION; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPATHOGENESIS; IMMUNOREACTIVITY; NEUTROPHIL; NEWBORN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBEPIDERMAL AUTOIMMUNE BLISTERING DERMATOSES;

AUTOANTIBODIES; BLISTER; CELL LINE; COLLAGEN TYPE VII; COMPLEMENT ACTIVATION; EPIDERMOLYSIS BULLOSA ACQUISITA; HEK293 CELLS; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLAMMATION; MOLECULAR SEQUENCE DATA; NEUTROPHILS; REACTIVE OXYGEN SPECIES; SKIN;

EID: 84905979920     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1400160     Document Type: Article

References (61)

1. Kerr, M. A. 1990. The structure and function of human IgA. Biochem. J. 271: 285-296.
2. Dechant, M., T. Beyer, T. Schneider-Merck, W. Weisner, M. Peipp, J. G. J. Van De Winkel, and T. Valerius. 2007. Effector mechanisms of recombinant IgA antibodies against epidermal growth factor receptor. J. Immunol. 179: 2936-2943.
3. Chintalacharuvu, K. R., and S. L. Morrison. 1996. Residues critical for H-L disulfide bond formation in human IgA1 and IgA2. J. Immunol. 157: 3443-3449.
4. Chintalacharuvu, K. R., L. J. Yu, N. Bhola, K. Kobayashi, C. Z. Fernandez, and S. L. Morrison. 2002. Cysteine residues required for the attachment of the light chain in human IgA2. J. Immunol. 169: 5072-5077.
5. Monteiro, R. C., and J. G. Van De Winkel. 2003. IgA Fc receptors. Annu. Rev. Immunol. 21: 177-204.
6. Johansen, F.-E., and C. S. Kaetzel. 2011. Regulation of the polymeric immunoglobulin receptor and IgA transport: new advances in environmental factors that stimulate pIgR expression and its role in mucosal immunity. Mucosal Immunol. 4: 598-602.
7. van Egmond, M., A. J. Van Vuuren, H. C. Morton, A. B. Van Spriel, L. Shen, F. M. Hofhuis, T. Saito, T. N. Mayadas, J. S. Verbeek, and J. G. Van De Winkel. 1999. Human immunoglobulin A receptor (FcalphaRI, CD89) function in transgenic mice requires both FcR gamma chain and CR3 (CD11b/CD18). Blood 93: 4387-4394.
8. Huls, G., I. A. Heijnen, E. Cuomo, J. Van Der Linden, E. Boel, J. G. Van De Winkel, and T. Logtenberg. 1999. Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies. Cancer Res. 59: 5778-5784.
9. Vidarsson, G., W. L. Van Der Pol, J. M. Van Den Elsen, H. Vilé, M. Jansen, J. Duijs, H. C. Morton, E. Boel, M. R. Daha, B. Corthésy, and J. G. Van De Winkel. 2001. Activity of human IgG and IgA subclasses in immune defense against Neisseria meningitidis serogroup B. J. Immunol. 166: 6250-6256.
10. Dechant, M., G. Vidarsson, B. Stockmeyer, R. Repp, M. J. Glennie, M. Gramatzki, J. G. Van De Winkel, and T. Valerius. 2002. Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing. Blood 100: 4574-4580.
11. Pasquier, B., P. Launay, Y. Kanamaru, I. C. Moura, S. Pfirsch, C. Ruffié, D. Hénin, M. Benhamou, M. Pretolani, U. Blank, and R. C. Monteiro. 2005. Identification of FcalphaRI as an inhibitory receptor that controls inflammation: dual role of FcRgamma ITAM. Immunity 22: 31-42.
12. Kanamaru, Y., H. Tamouza, S. Pfirsch, D. El-Mehdi, C. Guérin-Marchand, M. Pretolani, U. Blank, and R. C. Monteiro. 2007. IgA Fc receptor I signals apoptosis through the FcRgamma ITAM and affects tumor growth. Blood 109: 203-211.
13. Boross, P., S. Lohse, M. Nederend, J. H. M. Jansen, G. Van Tetering, M. Dechant, M. Peipp, L. Royle, L. P. Liew, L. Boon, et al. 2013. IgA EGFR antibodies mediate tumour killing in vivo. EMBO Mol. Med. 5: 1213-1226.
14. Woodley, D. T., R. A. Briggaman, E. J. O'Keefe, A. O. Inman, L. L. Queen, and W. R. Gammon. 1984. Identification of the skin basement-membrane autoantigen in epidermolysis bullosa acquisita. N. Engl. J. Med. 310: 1007-1013.
15. Woodley, D. T., R. E. Burgeson, G. Lunstrum, L. Bruckner-Tuderman, M. J. Reese, and R. A. Briggaman. 1988. Epidermolysis bullosa acquisita antigen is the globular carboxyl terminus of type VII procollagen. J. Clin. Invest. 81: 683-687.
16. Gammon, W. R., D. F. Murrell, M. W. Jenison, K. M. Padilla, P. S. Prisayanh, D. A. Jones, R. A. Briggaman, and S. W. Hunt, III. 1993. Autoantibodies to type VII collagen recognize epitopes in a fibronectin-like region of the noncollagenous (NC1) domain. J. Invest. Dermatol. 100: 618-622.
17. Burgeson, R. E. 1993. Type VII collagen, anchoring fibrils, and epidermolysis bullosa. J. Invest. Dermatol. 101: 252-255.
18. Zone, J. J., T.B. Taylor, L. J. Meyer, andM. J. Petersen. 1998. The 97 kDa linear IgA bullous disease antigen is identical to a portion of the extracellular domain of the 180 kDa bullous pemphigoid antigen, BPAg2. J. Invest. Dermatol. 110: 207-210.
19. Sárdy, M., S. Kárpáti, B. Merkl, M. Paulsson, and N. Smyth. 2002. Epidermal transglutaminase (TGase 3) is the autoantigen of dermatitis herpetiformis. J. Exp. Med. 195: 747-757.
20. Buijsrogge, J. J. A., G. F. H. Diercks, H. H. Pas, and M. F. Jonkman. 2011. The many faces of epidermolysis bullosa acquisita after serration pattern analysis by direct immunofluorescence microscopy. Br. J. Dermatol. 165: 92-98.
21. Sitaru, C., A. Kromminga, T. Hashimoto, E. B. Bröcker, and D. Zillikens. 2002. Autoantibodies to type VII collagen mediate Fcgamma-dependent neutrophil activation and induce dermal-epidermal separation in cryosections of human skin. Am. J. Pathol. 161: 301-311.
22. Shimanovich, I., S. Mihai, G. J. Oostingh, T. T. Ilenchuk, E.-B. Bröcker, G. Opdenakker, D. Zillikens, and C. Sitaru. 2004. Granulocyte-derived elastase and gelatinase B are required for dermal-epidermal separation induced by autoantibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid. J. Pathol. 204: 519-527.
23. Sitaru, C., S. Mihai, C. Otto, M. T. Chiriac, I. Hausser, B. Dotterweich, H. Saito, C. Rose, A. Ishiko, and D. Zillikens. 2005. Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen. J. Clin. Invest. 115: 870-878.
24. Woodley, D. T., C. Chang, P. Saadat, R. Ram, Z. Liu, and M. Chen. 2005. Evidence that anti-type VII collagen antibodies are pathogenic and responsible for the clinical, histological, and immunological features of epidermolysis bullosa acquisita. J. Invest. Dermatol. 124: 958-964.
25. Woodley, D. T., R. Ram, A. Doostan, P. Bandyopadhyay, Y. Huang, J. Remington, Y. Hou, D. R. Keene, Z. Liu, and M. Chen. 2006. Induction of epidermolysis bullosa acquisita in mice by passive transfer of autoantibodies from patients. J. Invest. Dermatol. 126: 1323-1330.
26. Herrero-González, J. E., J. M. Mascaró, Jr., C. Herrero, A. Dilling, D. Zillikens, and C. Sitaru. 2006. Autoantibodies from patients with BSLE inducing recruitment of leukocytes to the dermoepidermal junction and subepidermal splits in cryosections of human skin. Arch. Dermatol. 142: 1513-1516.
27. Sitaru, C., M. T. Chiriac, S. Mihai, J. Büning, A. Gebert, A. Ishiko, and D. Zillikens. 2006. Induction of complement-fixing autoantibodies against type VII collagen results in subepidermal blistering in mice. J. Immunol. 177: 3461-3468.
28. Mihai, S., M. T. Chiriac, K. Takahashi, J. M. Thurman, V. M. Holers, D. Zillikens, M. Botto, and C. Sitaru. 2007. The alternative pathway of complement activation is critical for blister induction in experimental epidermolysis bullosa acquisita. J. Immunol. 178: 6514-6521.
29. Sesarman, A., S. Mihai, M. T. Chiriac, F. Olaru, A. G. Sitaru, J. M. Thurman, D. Zillikens, and C. Sitaru. 2008. Binding of avian IgY to type VII collagen does not activate complement and leucocytes and fails to induce subepidermal blistering in mice. Br. J. Dermatol. 158: 463-471.
30. Chiriac, M. T., J. Roesler, A. Sindrilaru, K. Scharffetter-Kochanek, D. Zillikens, and C. Sitaru. 2007. NADPH oxidase is required for neutrophil-dependent autoantibody-induced tissue damage. J. Pathol. 212: 56-65.
31. Recke, A., C. Sitaru, G. Vidarsson, M. Evensen, M. T. Chiriac, R. J. Ludwig, and D. Zillikens. 2010. Pathogenicity of IgG subclass autoantibodies to type VII collagen: induction of dermal-epidermal separation. J. Autoimmun. 34: 435-444.
32. Ishii, N., A. Recke, S. Mihai, M. Hirose, T. Hashimoto, D. Zillikens, and R. J. Ludwig. 2011. Autoantibody-induced intestinal inflammation and weight loss in experimental epidermolysis bullosa acquisita. J. Pathol. 224: 234-244.
33. Ludwig, R. J., A. Recke, K. Bieber, S. Müller, Ade. C. Marques, D. Banczyk, M. Hirose, M. Kasperkiewicz, N. Ishii, E. Schmidt, et al. 2011. Generation of antibodies of distinct subclasses and specificity is linked to H2s in an active mouse model of epidermolysis bullosa acquisita. J. Invest. Dermatol. 131: 167-176.
34. Hirose, M., A. Recke, T. Beckmann, A. Shimizu, A. Ishiko, K. Bieber, J. Westermann, D. Zillikens, E. Schmidt, and R. J. Ludwig. 2011. Repetitive immunization breaks tolerance to type XVII collagen and leads to bullous pemphigoid in mice. J. Immunol. 187: 1176-1183.
35. van der Steen, L. P., J. E. Bakema, A. Sesarman, F. Florea, C. W. Tuk, G. Kirtschig, J. J. Hage, C. Sitaru, and M. Van Egmond. 2012. Blocking Fca receptor I on granulocytes prevents tissue damage induced by IgA autoantibodies. J. Immunol. 189: 1594-1601.
36. Kromminga, A., C. Scheckenbach, M. Georgi, C. Hagel, R. Arndt, E. Christophers, E. B. Bröcker, and D. Zillikens. 2000. Patients with bullous pemphigoid and linear IgA disease show a dual IgA and IgG autoimmune response to BP180. J. Autoimmun. 15: 293-300.
37. Christophoridis, S., L. Büdinger, L. Borradori, T. Hunziker, H. F. Merk, and M. Hertl. 2000. IgG, IgA and IgE autoantibodies against the ectodomain of BP180 in patients with bullous and cicatricial pemphigoid and linear IgA bullous dermatosis. Br. J. Dermatol. 143: 349-355.
38. Metz, B. J., S. Y. Ruggeri, S. Hsu, J. A. Reed, A. S. Ghohestani, J. Uitto, and R. F. Ghohestani. 2004. Linear IgA dermatosis with IgA and IgG autoantibodies to the 180 kDa bullous pemphigoid antigen (BP180): evidence for a distinct subtype. Int. J. Dermatol. 43: 443-446.
39. van der Steen, L., C.W. Tuk, J. E. Bakema, G. Kooij, A. Reijerkerk, G. Vidarsson, G. Bouma, G. Kraal, H. E. De Vries, R. H. J. Beelen, and M. Van Egmond. 2009. Immunoglobulin A: Fc(alpha)RI interactions induce neutrophil migration through release of leukotriene B4. Gastroenterology 137: 2018-2029.e1-3.
40. Otten, M. A., J. E. Bakema, C.W. Tuk, M. J. Glennie, A. L. Tutt, R. H. J. Beelen, J. G. J. Van De Winkel, and M. Van Egmond. 2012. Enhanced FcaRI-mediated neutrophil migration towards tumour colonies in the presence of endothelial cells. Eur. J. Immunol. 42: 1815-1821.
41. Boel, E., S. Verlaan, M. J. Poppelier, N. A. Westerdaal, J. A. Van Strijp, and T. Logtenberg. 2000. Functional human monoclonal antibodies of all isotypes constructed from phage display library-derived single-chain Fv antibody fragments. J. Immunol. Methods 239: 153-166.
42. Kang, D., Y. S. Gho, M. Suh, and C. Kang. 2002. Highly sensitive and fast protein detection with Coomassie brilliant blue in sodium dodecyl sulfatepolyacrylamide gel electrophoresis. Bull. Korean Chem. Soc. 23: 1511-1512.
43. Zillikens, D., Y. Kawahara, A. Ishiko, H. Shimizu, J. Mayer, C. V. Rank, Z. Liu, G. J. Giudice, H. H. Tran, M. P. Marinkovich, et al. 1996. A novel subepidermal blistering disease with autoantibodies to a 200-kDa antigen of the basement membrane zone. J. Invest. Dermatol. 106: 1333-1338.
44. Mestecky, J., R. G. Hamilton, C. G. Magnusson, R. Jefferis, J. P. Vaerman, M. Goodall, G. G. De Lange, I. Moro, P. Aucouturier, J. Radl, et al. 1996. Evaluation of monoclonal antibodies with specificity for human IgA, IgA subclasses and allotypes and secretory component. Results of an IUIS/WHO collaborative study. J. Immunol. Methods 193: 103-148.
45. Katz, S. I., K. C. Hertz, and H. Yaoita. 1976. Herpes gestationis. Immunopathology and characterization of the HG factor. J. Clin. Invest. 57: 1434-1441.
46. R Development Core Team. 2012. R: A Language and Environment for Statistical Computing, version 2.15. R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org.
47. Myrsky, E., K. Kaukinen, M. Syrjänen, I. R. Korponay-Szabó, M. Mäki, and K. Lindfors. 2008. Coeliac disease-specific autoantibodies targeted against transglutaminase 2 disturb angiogenesis. Clin. Exp. Immunol. 152: 111-119.
48. Walker, J. M. 2009. The Protein Protocols Handbook. Humana Press, New York, NY.
49. Yu, X., K. Holdorf, B. Kasper, D. Zillikens, R. J. Ludwig, and F. Petersen. 2010. FcgRIIA and FcgRIIIB are required for autoantibody-induced tissue damage in experimental human models of bullous pemphigoid. J. Invest. Dermatol. 130: 2841-2844.
50. Sandin, C., S. Linse, T. Areschoug, J. M. Woof, J. Reinholdt, and G. Lindahl. 2002. Isolation and detection of human IgA using a streptococcal IgA-binding peptide. J. Immunol. 169: 1357-1364.
51. Horton, R. E., and G. Vidarsson. 2013. Antibodies and their receptors: different potential roles in mucosal defense. Front. Immunol. 4: 200.
52. Bakema, J. E., and M. Van Egmond. 2011. The human immunoglobulin A Fc receptor FcaRI: a multifaceted regulator of mucosal immunity. Mucosal Immunol. 4: 612-624.
53. Bogers, W. M., R. K. Stad, L. A. Van Es, and M. R. Daha. 1991. Immunoglobulin A: interaction with complement, phagocytic cells and endothelial cells. Complement Inflamm. 8: 347-358.
54. Hiemstra, P. S., A. Gorter, M. E. Stuurman, L. A. Van Es, and M. R. Daha. 1987. Activation of the alternative pathway of complement by human serum IgA. Eur. J. Immunol. 17: 321-326.
55. Roos, A., L. H. Bouwman, D. J. Van Gijlswijk-Janssen, M. C. Faber-Krol, G. L. Stahl, and M. R. Daha. 2001. Human IgA activates the complement system via the mannan-binding lectin pathway. J. Immunol. 167: 2861-2868.
56. Liu, Z., W. Sui, M. Zhao, Z. Li, N. Li, R. Thresher, G. J. Giudice, J. A. Fairley, C. Sitaru, D. Zillikens, et al. 2008. Subepidermal blistering induced by human autoantibodies to BP180 requires innate immune players in a humanized bullous pemphigoid mouse model. J. Autoimmun. 31: 331-338.
57. Qaqish, B. F., P. Prisayanh, Y. Qian, E. Andraca, N. Li, V. Aoki, G. Hans-Filho, V. dos Santos, E. A. Rivitti, and L. A. Diaz, Cooperative Group on Fogo Selvagem Research. 2009. Development of an IgG4-based predictor of endemic pemphigus foliaceus (fogo selvagem). J. Invest. Dermatol. 129: 110-118.
58. Sitaru, C., C. Dähnrich, C. Probst, L. Komorowski, I. Blöcker, E. Schmidt, W. Schlumberger, C. Rose, W. Stöcker, and D. Zillikens. 2007. Enzyme-linked immunosorbent assay using multimers of the 16th non-collagenous domain of the BP180 antigen for sensitive and specific detection of pemphigoid autoantibodies. Exp. Dermatol. 16: 770-777.
59. Recke, A., I. Shimanovich, P. Steven, L. Westermann, D. Zillikens, and E. Schmidt. 2011. [Treatment-refractory anti-laminin 332 mucous membrane pemphigoid. Remission following adjuvant immunoadsorption and rituximab]. Hautarzt 62: 852-858.
60. Schmidt, E., and D. Zillikens. 2010. Immunoadsorption in dermatology. Arch. Dermatol. Res. 302: 241-253.
61. Eming, R., and M. Hertl. 2006. Immunoadsorption in pemphigus. Autoimmunity 39: 609-616.